A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...
Bionova Scientific announced Thursday it would bring 200 new jobs to The Woodlands over the next several years, bolstering ...
How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...
While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...
T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...
For kids with the condition, day-to-day activities like going to school or playing with friends can lead to life-threatening ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...
The Cambridge research institute launched nearly two years ago with $500 million to support scientific research and development. Approximately 50 staff members will be laid off.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback